- 1 Research article: Instrumental and Laboratory Changes in Post-Myocardial Infarction
- 2 Prognosis: A Cross-Sectional Analysis
- 3 Running tittle: Current Advances in Cardiopathologies Management
- 5 Authors' list: Basheer Abdullah Marzoog^{1,*}, Natalia Igorevna Bloshkina², Vera
- 6 Sergeevna Gromova³, Irina Andreevna Bakarova⁴, Natalia Rudolfovna Chemekova²,
- 7 Elena Ivanovna Gorshinina²
- 9 ¹ World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M.
- 10 Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow,
- Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.
- ² National Research Mordovia State University. Address: Bolshevitskaya Street, 68, Saransk,
- Rep. Mordovia, Russia. Postal address: Russia, Mordovia republic, Saransk, Bolshevitskaya
- 14 Street, 31, 430005.

8

26

- ³ Immanuel Kant Baltic Federal University, Russia, Kaliningrad, Alexander Nevsky Street,
- 16 14. ORCID 0000-0002-8707-8876
- ⁴ I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991
- 18 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. ORCID
- 19 0009-0007-5333-4935
- ^{*}Corresponding author: Basheer Abdullah Marzoog, Ph.D. student at Sechenov First Moscow
- 21 State Medical University at the World-Class Research Center "Digital biodesign and
- personalized healthcare". (marzug@mail.ru, +79969602820). Address: Russia, Moscow, 8-2
- Trubetskaya street, 119991. Postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.
- 24 ORCID: 0000-0001-5507-2413, Scopus ID: 57486338800
- 25 Competing interests: No competing interests regarding the publication.
- 27 All authors read and approved the final version of the manuscript

- 35 **Abstract**
- **Background:** Cardiovascular events continue to be a leading cause of death worldwide.
- 37 **Aims**: To evaluate the early laboratory and instrumental changes in a systematic manner in
- patients who experienced a recent myocardial infarction (MI).
- 39 **Objectives:** To study patients with myocardial infarction occurring within 30 days prior to
- 40 hospitalization in a rehabilitation hospital.
- 41 Materials and methods: A large-scale retrospective cohort sectional study was conducted
- 42 from 2014 to 2019, using data collected from Mordovia Rehabilitation Hospital. The study
- 43 included 154 patients, with analysis of 76 parameters for each patient. Statistical analysis was
- 44 performed using the Statistica program, employing t-tests, Pearson's correlation coefficient,
- and ROC tests.
- 46 **Results**: The sample consisted of 154 patients with a history of recent myocardial infarction.
- Of the total, 51 (33.11%) were female and 103 (66.88%) were male. Among the patients, 42
- 48 (27.27%) had chronic heart failure (CHF), while 101 (65.58%) did not, and 11 (7.142%) had
- missing data. Diabetes mellitus (DM) was observed in 28 (18.18%), with 118 (76.62%)
- without DM. Hypertension was present in 118 (76.62%), while 28 (18.18%) did not have
- 51 hypertension. Chronic kidney disease (CKD) was seen in 11 (7.14%), with 131 (85.064%)
- 52 not having CKD. Chronic obstructive pulmonary disease (COPD) was present in 14 (9.09%),
- 53 while 132 (85.71%) did not have COPD. Post-myocardial infarction (MI) CHF was observed
- 54 in 108 (70.13%), with 42 (27.27%) not having CHF. Post-MI arrhythmia was seen in 50
- 55 (32.47%) patients, while 99 (64.28%) did not have arrhythmia. Early post-MI complications,
- such as aneurysm, were present in 12 (7.79%), with 138 (89.61%) not having aneurysm.
- 57 Dressler syndrome (pericarditis) was seen in 4 (2.59%) patients, pneumonitis in 1 (0.64%),
- and pleuritis was not observed.
- 59 Conclusions: Systemic manifestations of myocardial infarction include kidney function
- 60 impairment or the development of new kidney disease. These changes involve an increase in
- 61 aorta basement diameter, right ventricle enlargement, decrease in serum red blood cell levels,
- 62 serum potassium and calcium levels, and an increase in serum myoglobin. Elevated
- 63 myoglobin levels are associated with the development of chronic heart failure. Higher
- creatinine levels and/or LDH are linked to the occurrence of arrhythmia. Hypertension is the
- 65 predominant comorbid condition in MI patients, and arrhythmia is the most commonly
- 66 reported post-MI complication.
- Other findings: Females are more susceptible to post-MI urinary tract infections.

- 68 **Keywords**: Myocardial infarction, Cardiology, Myocardiopathies, Myocardiocyte,
- Angiogenesis & Regeneration

Introduction

70717273

- 74 Myocardial infarction (MI) and associated sequalae remain the most reported cause of
- 75 mortality and morbidity worldwide [1]. The development of cardiovascular events is
- associated with several modified and non-modified risk factors [2]. Lifestyle changes have a
- 77 huge impact on the overall health of the cardiovascular system [3, 4]. Unfortunately,
- sedentary lifestyle is seen in majority of myocardial infarction, which is associated with
- 79 development of several predisposition factors for cardiovascular events such as
- 80 dyslipidaemia, insulin resistance, and central obesity or visceral obesity [5–9]. Collectively,
- 81 these early signs of disturbance of cardiovascular homeostasis are ignored to provoke the
- 82 progression of dyslipidaemia and insulin resistance to reach enough levels to induce the
- emergence of cardiovascular events such as MI [10, 11].
- Assessment of the early post-MI changes is of huge impact on the further therapy plan and
- the prognosis of MI victims. One of the early specific markers of myocardial infarction is the
- 86 elevation of cardiac lactate dehydrogenase 1 and troponins, including troponins I and T.
- 87 However, systemic changes are rarely assessed in early pot-MI patients [12]. The role of
- 88 these changes is unclear in determining the prognosis of patients with MI and the potential
- 89 risk of developing complications such as renal failure. In the current retrospective analysis,
- 90 we covered the potential role of these systemic and the regularly checked cardiac markers in
- 91 the prognosis determination and prognosis of the patients [5, 8, 20–23, 9, 13–19].

Materials and methods

- 93 A retrospective cohort analysis for 154 patients for the period 2014-2019. The data was
- 94 collected from the republican rehabilitation hospital (history of the patients from the other
- 95 hospitals are collected in the rehabilitation hospital, that is why we collected the data from
- 96 her). All the presented data are after first contact with the patient and shows the peak values
- 97 of post MI changes. Consent from patients has been taken for the collection, analysis, and
- 98 publication the material and any associated photos or graphs. The missing data treated as
- 99 absent and removed from the analysis. All measurement units are based on the local units
- used in the laboratories. There was no access to the 2020-2022 year data because of the
- 101 COVID-19 pandemic. Pleuritis was not seen in patients and been excluded from the

- 102 complications report. The results of the presented t-test are all statistically significant, and
- other results are not statistically significant at p<0.05. The level of leukocytes and red blood
- 104 cell level is always mentioned without *10⁹ or *10¹², respectively. We could not assess the
- risk hazard for the estimated parameters and the survival rate, limitations of the study.
- The T test, the Pearson correlation coefficient and ROC analysis have been used using the
- 107 Statistica 12 programme (StatSoft, Inc. (2014). STATISTICA (data analysis software
- system), version 12. www.statsoft.com.).
- 109 Results
- The sample consisted of 154 patients with a history of recent myocardial infarction. Out of
- the total, 51 (33.11%) were female and 103 (66.88%) were male. Among the patients, 131
- 112 (85.064%) lived in the city, 17 (11.038%) lived in the village, and 5 (3.24%) lived in the
- 113 town.

- A majority of the patients had a concomitant disease prior to their myocardial infarction. Of
- these, 132 (85.71%) had a concomitant disease, 18 (11.68%) did not have a concomitant
- disease, and 4 (2.59%) had missing data. Among the concomitant diseases, chronic heart
- failure (CHF) was observed in 42 (27.27%) patients, while 101 (65.58%) did not have CHF,
- and 11 (7.14%) had missing data. Diabetes mellitus (DM) was observed in 28 (18.18%), with
- 120 118 (76.62%) without DM, and 8 (5.19%) having missing data. Hypertension was present in
- 121 118 (76.62%), while 28 (18.18%) did not have hypertension, and 8 (5.19%) had missing data.
- 122 Chronic kidney disease (CKD) was observed in 11 (7.14%) patients, with 131 (85.064%) not
- having CKD, and 12 (7.79%) having missing data. Chronic obstructive lung disease (COPD)
- existed in 14 (9.09%), while 132 (85.71%) did not have COPD, and 8 (5.19%) had missing
- data. Disrupted lipid profile was present in 21 (13.63%), while 121 (78.57%) did not have
- dyslipidemia, and 12 (7.79%) had missing data. Varicose veins were observed in 3 (1.94%),
- while 137 (88.96%) did not have varicose veins, and 14 (9.09%) had missing data.
- 129 In terms of complications after myocardial infarction, 145 (94.15%) patients experienced a
- complication, 5 (3.24%) did not have a complication, and 4 (2.59%) had missing data. Post-
- myocardial infarction (MI) chronic heart failure (CHF) was observed in 108 (70.12%)
- patients, while 42 (27.27%) did not have CHF, and 4 (2.59%) had missing data. Post-MI
- arrhythmia was seen in 50 (32.47%) patients, while 99 (64.28%) did not have arrhythmia, and
- 5 (3.24%) had missing data. Early post-MI complications, such as aneurysm, were observed
- in 12 (7.79%) patients, while 138 (89.61%) did not have aneurysm, and 4 (2.59%) had

136 missing data. Late post-MI complications, including Dressler syndrome with pericarditis, 137 were seen in 4 (2.59%) patients, while 146 (94.80%) did not have pericarditis, and 4 (2.59%) 138 had missing data. Pneumonitis, another component of Dressler syndrome, was observed in 1 139 (0.64%) patient, while 148 (96.10%) did not have pneumonitis, and 5 (3.24%) had missing 140 data. Notably, pleuritis, the third component of Dressler syndrome, was not observed and 141 therefore not reported. 142 Interestingly, 43 (27.92%) patients experienced a re-infarct, while 107 (69.48%) had their 143 first infarction, and 4 (2.59%) had missing data. Evaluation of tissue-type plasminogen 144 activator (t-PA) activity level through serum measurement showed elevated levels in 7 145 (4.54%) patients, normal levels in 5 (3.24%), and 142 (92.20%) patients did not have their d-146 dimer level measured. 147 The primary descriptive statistics demonstrated in (*Table 1*). 148 Table 1: The primary descriptive statistics of the sample. Abbreviations: EF; ejection 149 fraction, EDV; end diastolic volume, LV; left ventricle, LA; left atrium, RV; right ventricle, RA; right atrium, Hb; hemoglobin, RBC; red blood cell, ESR; erythrocyte sedimentation rate 150 151 of erythrocytes, CKP-MB; creatinine phosphokinase-MB fraction, LDH; lactate 152 dehydrogenase, ALT; alanine transaminase, AST; aspartate transaminase, LDL; low density lipoprotein, TAG; triacyl glycerides, APTT; activated prothrombin time, PT; prothrombin 153 154 time.

	Descriptive Statistics							
Variable	Valid N	% Valid obs.	Mean	Median	Minimum	Maximum		
Hospitalization	153	99.35	14.53	15.0	0.00	24		
days								
Age (years)	152	98.70	61.64	62.5	30.00	86		
Body weight (Kg)	31	20.12	82.26	85.000	62.00	112		
Height (cm)	31	20.12	170.58	172.00	155.0	185		
BMI (Kg/m ²)	31	20.12	28.56	27.88	21.79	41		
HR (beat/mint)	148	96.10	79.82	78.00	53.00	130		
SBP (mmHg)	148	96.10	139.57	140.00	60.00	260		
DBP (mmHg)	148	96.10	84.05	80.00	40.00	130		
Aorta diameter at	144	93.50	35.21	35.00	20.00	46		
the Valsalva								
sinuses (mm)								

	Descriptive Statistics							
Variable	Valid N	% Valid obs.	Mean	Median	Minimum	Maximum		
EF (%)	142	92.20	54.55	55.000	25.00	80		
EDV of the LV	113	73.37	134.30	129.00	62.00	234		
(ml)								
End diastolic size	132	85.71	52.35	51.150	10.00	89		
of the LV (mm)								
End diastolic size	133	86.36	40.09	40.00	28.00	62		
of the LA (mm)								
End diastolic size	144	93.50	26.75	26.25	5.00	44		
of the RV (mm)								
End diastolic size	130	84.41	35.73	36.00	24.00	49		
of the RA (mm)								
Hb	143	92.85	137.10	138.0	85.00	170		
Leukocytes (/L)	141	91.55	8.82	8.30	2.80	18		
RBC (/L)	118	76.62	5.12	4.50	2.60	24		
Lymphocytes (%)	130	84.41	25.51	25.50	2.00	54		
Thrombocytes (/L)	111	72.07	206.76	200.00	83.00	506		
ESR (mm/hr)	138	89.61	19.04	15.50	2.00	60		
Urine ketones	1	0.64	0.50	0.50	0.50	1		
(mmol/l)								
Urine proteins	137	88.96	5.27	0.00	0.00	150		
(mmol/l)								
Urine leukocytes	142	92.20	2.64	1.00	0.00	50		
(microscopically)								
Urine epithelial	136	88.31	1.86	1.000	0.00	20		
cells								
(microscopically)								
Troponin I (ng/ml)	126	81.81	4.74	1.20	0.00	33		
Myoglobin (ng/ml)	3	1.94	111.30	71.0	63.00	200		
CKP-MB 1 (U/l)	129	83.76	97.01	29.0	6.00	2881		
CKP-MB 2 (U/l)	71	46.10	79.26	42.0	6.00	508		

	Descriptive Statistics						
Variable	Valid N	% Valid obs.	Mean	Median	Minimum	Maximum	
LDH 1 (U/l)	108	70.12	652.30	475.5	30.00	3900	
LDH 2 (U/l)	56	36.36	21640.80	492.0	97.00	1177	
INR (Sec)	125	81.16	1.25	1.00	0.80	18	
Total bilirubin (mmol/l)	108	70.12	16.53	17.68	4.42	36	
ALT (mmol/l)	140	90.90	42.65	28.00	1.19	361	
AST (mmol/l)	140	90.90	55.57	30.00	5.10	423	
Total cholesterol (mmol/l)	141	91.55	5.23	5.10	2.40	9	
LDL (mmol/l)	138	89.61	23.20	3.24	0.92	2766	
TAG (mmol/l)	140	90.90	3.65	1.56	0.27	138	
Na (mmol/l)	122	79.22	139.76	142.75	1.76	151	
K (mmol/l)	126	81.81	6.02	4.06	1.00	92	
Creatinine (µmol/L)	142	92.20	81.56	84.00	0.00	176	
Ca (mmol/l)	115	74.67	1.69	1.18	0.25	38	
Urea (mmol/l)	139	90.25	7.79	6.70	2.50	93	
Glucose (mmol/l)	135	87.66	6.86	6.10	4.00	19	
APTT (Sec)	74	48.05	27.31	25.50 15.00		76	
Fibrinogen (ng/ml)	117	75.97	3386.85	3500.00	300.00	7500	
PT (Sec)	1	0.64	94.00	94.00	94.00	94	

Males are affected by myocardial infarction earlier than females; the age cut-off point is 67 years old. (*Figure 1*)

The mean age in the male group was 59.76 years, while in the female group it was 65.46 years. This difference was statistically significant, with a t-value of 3.30 (p<0.001). Similarly, the mean height of males was 172.57 cm, whereas in females it was 164.88 cm, showing a statistically significant difference with a t-value of -3.26 (p<0.002). The mean diameter of the aorta on echocardiogram was 36.23 mm in males and 33.04 mm in females, which also exhibited a statistically significant difference with a t-value of -4.24 (p<0.00003). Regarding right atrium size, the mean in males was 36.26 mm, compared to 34.56 mm in females,

showing a statistically significant difference with a t-value of -2.06 (p<0.04). Hemoglobin levels in men had a mean of 140.26, while in women it was 130.66, demonstrating a statistically significant difference with a t-value of -3.71 (p<0.0002).

In urine analysis, the mean number of leukocytes under microscope in the male group was 1.52, whereas in the female group it was 4.91, with a statistically significant difference and a t-value of 3.11 (p<0.002). Additionally, the number of epithelial cells in the male group was 1.36, compared to 2.91 in the female group, showing a statistically significant difference with a t-value of 3.12 (p<0.002). The mean myoglobin level in males was 67.00 ng/ml, while in females it was 199.90 ng/ml, which exhibited a highly significant difference with a t-value of 19.18 (p<0.03). (*Table 2*)

Table 2: Gender role in the numerical variables.

	T-tests; Gro	uping: Gend	ler							
Variable	Group 1: F									
	Group 2: M	*								
	Mean	Mean	t-value	df	p	Valid N	Valid N			
	F	M				F	M			
Hospitalization days	14,42	14,58	-0,26	151	0,78	50	103			
Age	65,46	59,76	3,30	150	0,001	50	102			
Body weight	83,38	81,87	0,30	29	0,75	8	23			
Height	164,88	172,57	-3,26	29	0,002	8	23			
BMI	31,20	27,48	1,94	29	0,06	9	22			
HR	80,08	79,70	0,13	146	0,89	49	99			
SBP	144,18	137,29	1,39	146	0,16	49	99			
DBP	85,71	83,23	1,10	146	0,27	49	99			
Aorta diameter at	33,04	36,23	-4,24	142	0,00003	46	98			
Valsalva Sinus										
EF	55,27	54,22	0,62	140	0,53	45	97			
EDV	128,08	137,33	-1,30	111	0,19	37	76			
LV	51,76	52,65	-0,62	130	0,53	44	88			
LA	40,16	40,06	0,09	131	0,92	41	92			
RV	26,20	27,01	-0,98	142	0,32	46	98			
RA	34,56	36,26	-2,06	128	0,040	40	90			
Hb	130,66	140,26	-3,71	141	0,00029	47	96			
Leukocytes	8,40	9,02	-1,16	139	0,24	45	96			
RBC	4,80	5,28	-0,81	116	0,41	40	78			
Lymphocytes	27,62	24,50	1,77	128	0,07	42	88			
Thrombocytes	193,69	213,83	-1,54	109	0,12	39	72			
ESR	21,52	17,88	1,53	136	0,12	44	94			
Urine proteins	4,05	5,85	-0,43	135	0,6	44	93			
leukocytes	4,91	1,52	3,11	140	0,002	47	95			
Epithelial cells	2,91	1,36	3,12	134	0,002	44	92			

	T-tests; Grouping: Gender								
Variable	Group 1: F								
	Group 2: M								
	Mean	Mean	t-value	df	p	Valid N	Valid N		
	F	M				F	M		
Troponin I	3,39	5,34	-1,23	124	0,21	39	87		
Myoglobin	199,90	67,00	19,18	1	0,033	1	2		
CKP-MB	94,57	98,14	-0,06	127	0,94	41	88		
LDH	630,78	661,36	-0,25	106	0,79	32	76		
INR	1,01	1,36	-1,16	123	0,24	39	86		
Total bilirubin	15,96	16,80	-0,61	106	0,53	35	73		
ALT	51,77	38,33	1,59	138	0,11	45	95		
AST	57,66	54,58	0,28	138	0,77	45	95		
Total choles	5,42	5,14	1,138	139	0,25	45	96		
LDL	3,30	3,12	0,90	136	0,36	43	95		
TAG	1,88	1,67	1,24	138	0,21	45	95		
Na	141,81	138,90	0,78	120	0,43	36	86		
K	3,87	6,95	-1,20	124	0,23	38	88		
Creatinine	81,23	81,72	-0,09	140	0,92	45	97		
Ca	1,53	1,76	-0,31	113	0,75	36	79		
Urea	7,15	8,10	-0,54	137	0,58	45	94		
Glucose	7,12	6,74	0,79	133	0,42	43	92		
APTT	25,82	27,94	-0,93	72	0,35	22	52		
Fibrinogen	3490,73	3346,04	0,86	115	0,39	33	84		

Patients with concomitant diseases have a mean heart rate (HR) equal to 80.82 beats / minute and patients without concomitant disease have a mean HR equal to 72.39 beats / minute, which is a statistically significant difference, t value 2.05, p< 0.04. Furthermore, patients with concomitant diseases have a mean diastolic size of the right ventricle of 27.13 mm and patients without concomitant disease have a mean diastolic size of the right ventricle is 23.85 mm, which is a statistically significant difference, t value 2.79, p< 0.005. Moreover, patients with concomitant disease have a mean protein in urine 3.18 mg/l, and the patients without concomitant disease had a mean level of urine protein 21.25 mg/l, which is statistically significant difference, t value -3.10, p< 0.002. Interestingly, patients with concomitant disease had lower calcium level a mean equal to 1.31 mmol/l and the patients without concomitant disease had a mean calcium level 3.84 mmol/l, which is statistically significant difference, t value -2.67, p< 0.008. (*Figure 2*)

Patients with CHF have a mean thrombocyte level equal to 185.26 / l, while patients without CHF have a mean thrombocyte level of 216.24 /l, which is a statistically significant difference, t value - 2.15, p< 0.03.

- Mean glucose level in diabetic patients equal to 9.93 mmol/l and in non-diabetic patients
- equal to 6.13 mmol/l, which is statistically significant difference, t value -7.97, p< 0.0001.
- The coexistence of DM in patients increases the mean diastolic size of the left ventricle 55.60
- mm, while, in patients without DM, the mean diastolic size of the left ventricle equals 51.42
- 197 mm, which is a statistically significant difference, t value -2.53, p< 0.012. The mean
- sedimentation rate (ESR) in patients with DM equals 23.60 mm/hr, and equal to 17.43 mm/hr
- in non-diabetic patients, which is statistically significant difference, t value -2.22, p< 0.027.
- The mean creatinine phosphokinase-MB fraction is dramatically higher in patients with DM
- 201 233.36 U/L and lower in non-diabetic patients 66.05 U / L, which is a statistically significant
- 202 difference, t value --2.62, p< 0.009. Diabetic patients experience a high level of triacyl
- 203 glyceride (TAG) 2.17 mmol / l, while non-diabetic patients had a lower TAG level of 1.66
- 204 mmol/l, which is a statistically significant difference, t value -2.56, p< 0.011.
- 205 Hypertensive patients have a low mean level of red blood cells (RBC) level 4.55 /l in
- 206 compare to non-hypertensive patients 7.7, which is statistically significant difference, t value
- 207 -4.63276, p< 0.000010. In hypertensive patients, the mean LDH 1 is 608.21 U/l, INR is 1.05,
- sodium is 141.70 mmol/l, potassium is 4.04 mmol/l, and calcium is 1.14 mmol/l, whereas, in
- 209 non-hypertensive patients, the mean level of LDH 1 is 908.8 U/l, INR is 2.1, sodium is 130.6
- 210 mmol/l, potassium is 14.8 mmol/l, calcium is 3.9 mmol/l, which is statistically significant
- 211 difference; t value -2.07, -3.04, 2.51, -3.62, -3.19; p< 0.04, 0.0028, 0.013, 0.0004, 0.001,
- 212 respectively.
- 213 CKD patients have a high mean troponin I level equal to 22.70 ng/ml compared to non-CKD
- patients 3.72 ng/ml, which is a statistically significant difference, t value -6.84, p< 0.0001.
- Also, CKD patients have higher mean level of CPK-MB fraction equal to 475.61 U/l in
- compare to non-CKD patients equal to 78.38 U/l, which is statistically significant difference,
- 217 t value -3.63, p< 0.0004. The mean creatinine level is higher in patients with CKD at 109.81
- 218 µmol/L comparing to non-CKD patients, which is a statistically significant difference, t value
- 219 -3.63, p< 0.0004.
- 220 Interestingly, patients with COPD have a mean diastolic size of the left ventricle of 48.46
- 221 mm, which is less than that of patients 52.73 mm, which is a statistically significant
- 222 difference, t value 1.99, p< 0.048. However, patients with COPD have a mean diastolic size
- of the right atrium is 39.55 mm compared to patients 35.41 mm, which is a statistically
- significant difference, t value -3.06, p< 0.002. Furthermore, COPD patients have a mean level
- of RBC equal to 145.29 compared to non-COPD patients 136.39, which is a statistically
- significant difference, t value -2.11, p< 0.03.

227 Patients with dyslipidemia have mean troponin I 9.4 ng/ml, whereas, patients without 228 dyslipidemia have mean troponin I 3.64 ng/ml, which is statistically significant difference, t 229 value -2.99, p< 0.003. Additionally, patients with dyslipidemia have mean total bilirubin 19.3 230 mmol / 1 and 15.72 mmol/l in patients without dyslipidaemia, which is a statistically 231 significant difference, t value -2.12, p< 0.03. Furthermore, patients with dyslipidaemia have a 232 mean serum sodium level of 132.3 mmol/l and a mean serum potassium level of 8.4 mmol/l, 233 while in patients without dyslipidaemia, the mean sodium serum level is 142.24 mmol/l and a 234 mean serum potassium level of 4.07 mmol/l, which is a statistically significant difference; t 235 value 2.74, -2.09; p< 0.006, 0.03. 236 The mean leukocytes level in patients with varicose veins is 12.07 /l, whereas, in patients 237 without varicose veins, the mean leukocytes level is 8.71 /l, which is statistically significant 238 difference; t value -1.99, p< 0.04. The mean RBC level in patients with varicose veins is 239 9.87 /l, whereas, in patients without varicose veins, the mean RBC level is 4.56 /l, which is 240 statistically significant difference; t value -6.88, p< 0.00. The mean level of ESR in patients 241 with varicose veins is 37.67 mm / h, while, in patients without varicose veins, the mean ESR 242 level is 18.25 mm / h, which is statistically significant difference; t value -2.64, p< 0.009. 243 In terms of complications, patients with complications have been hospitalized for 14.65 days, 244 whereas, patients without complications hospitalized for 11.40 days, which is statistically significant difference; t value 2.05, p< 0.04. In patients with complications, the mean aorta 245 246 diameter 35.38 mm, whereas, in patients without complications, the mean aorta diameter 247 29.25 mm, which is statistically significant difference; t value 2.77, p< 0.006. In patients with 248 complications, the mean diastolic size is of the right ventricle is 26.89 mm, while, in patients 249 without complications, the mean diastolic size of the right ventricle 21.25mm, which is a 250 statistically significant difference; t 2.44, p< 0.01. In patients with complications, the mean 251 level of RBC 4.87 / l, while in patients without complications, the mean level of RBC 12.40 252 /l, which is a statistically significant difference; t value -5.37, p< 0.0001. In patients with 253 complications, in the general urine analysis, microscopically, the mean level of urea proteins 254 4.30, while, in patients without complications, the mean level of urea proteins 50.00, which is 255 a statistically significant difference; t -3.61, p< 0.0004. In patients with complications, the 256 mean potassium level 5.37 mmol/l and mean calcium level 1.58 mmol/l, whereas, in patients 257 without complications, the mean potassium level 32.99 mmol/l and mean calcium level is 258 5.99 mmol/l, which is statistically significant difference; t value -3.75, -2.05; p< 0.0002, 0.04, 259 respectively.

260 Patients with post-MI CHF have mean myoglobin level 199.90 ng/ml, whereas, in patients 261 without post-MI CHF, the mean myoglobin level 67.00 ng/ml, which is statistically 262 significant difference; t value 19.18, p< 0.033. 263 Patients with a history of previous infarction have creatinine 90.48 µmol/l in compare to 264 patients without reinfarction 78.01 µmol/l, which is a statistically significant difference; t 265 value 2.26, p< 0.02 266 The mean age of patients with arrythmia is 65.58 years, while the mean age of patients 267 without arrythmia is 59.68 years, which is statistically significant difference; t value 3.32, p< 268 0.001. The mean height of patients with arrythmia is 173.67 cm, while the mean height of 269 patients without arrythmia is a 168.61 cm, which is statistically significant difference; t value 270 2.23, p< 0.03. The mean ejection fraction (EF) of patients with arrythmia is 50.40 %, while 271 the mean EF of patients without arrythmia is a 56.43 %, which is statistically significant 272 difference; t -3.81, p< 0.0002. The mean diastolic size of the left atrium of patients with 273 arrythmia is 42.14 mm, while the mean diastolic size of the left atrium of patients without 274 arrythmia is 39.12 mm, which is statistically significant difference; t 3.00, p< 0.003. The 275 mean diastolic size right atrium of patients with arrythmia is 37.36 mm, whereas, the mean 276 diastolic size of the right atrium of patients without arrythmia is 34.95 mm, which is 277 statistically significant difference; t value 2.96, p< 0.003. The mean CKP-MB of patients 278 with arrythmia is 181.82 U / l, while the mean CKP-MB of patients without arrythmia is a 279 56.68 U/l, which is statistically significant difference; t 2.34, p< 0.02. The mean serum 280 lactate dehydrogenase (LDH) level of patients with arrythmia is 888.37 U/l, whereas, the 281 mean lactate dehydrogenase level of patients without arrythmia is a 533.49 U/l, which is 282 statistically significant difference; t value 3.16, p< 0.002. The mean serum level of aspartate 283 transaminase of patients with arrythmia is 71.53 mmol / l, while the mean lactate 284 dehydrogenase serum level of patients without arrythmia is a 47.38 mmol/l, which is 285 statistically significant difference; t value 2.23, p< 0.026. The mean EF of patients with aneurysm is 43.00 %, whereas, the mean EF of patients without 286 287 aneurysm is 55.59 %, which is statistically significant difference; t value 4.57, p< 0.00001. 288 The mean level in patients with aneurysm is 9.70 / 1, while the mean level of patients without 289 aneurysm is a 2.11 /l, which is statistically significant difference; t -3.83, p< 0.0001. The 290 mean epithelial cell level in general urine analysis in patients with aneurysm is 5.40, whereas, 291 the mean epithelial cell level in patients without aneurysm is 1.58, which is statistically 292 significant difference; t value -4.41, p< 0.00002.

- 293 The mean diastolic size of the left atrium of patients with pericarditis is 45.5 mm, while the 294 mean diastolic size of the left atrium of patients without pericarditis is a 39.90 mm, which is 295 statistically significant difference; t value -2.01, p< 0.04. The mean creatinine level of 296 patients with pericarditis is 52.5 µmol/L, whereas, the mean creatinine level of patients 297 without pericarditis is 82.39 µmol/L, which is statistically significant difference; t value 1.98, 298 p < 0.048. 299 Patients with pneumonitis have mean aorta diameter of 20.00 mm, whereas, the mean aorta 300 diameter of patients without pneumonitis is 35.32 mm, which is statistically significant 301 difference; t value 3.55, p< 0.0005. Patients with pneumonitis have mean serum leukocytes 302 level of 14.80 /l, whereas, the mean serum leukocytes level of patients without pneumonitis is 303 8.70 /l, which is statistically significant difference; t value -2.11, p< 0.036. Patients with 304 pneumonitis have a mean ESR level of 48.00 mm / hour, while the mean ESR level of 305 patients without pneumonitis is an 18.47 mm/he, which is statistically significant difference; t 306 value -2.36, p< 0.019. Furthermore, patients with pneumonitis have a mean leukocyte level of 307 22.00, whereas, the mean urine leukocyte level in urine of patients without pneumonitis is a 308 2.53, which is statistically significant difference; t value -3.15, p< 0.001. The mean CKP-MB 309 in patients with pneumonitis is 1164.00 U / I, while the mean CKP-MB in patients without 310 pneumonitis is a 89.60 U/l, which is statistically significant difference; t -3.92, p< 0.0001. 311 The mean diameter of the aorta, EF, EDV, troponin I, CKP-MB, and APTT in patients with 312 elevated troponin T is 28.00 mm, 36.00 %, 62.00 ml, 33.00 ng/ml, 2881.00 U / l, and 49.10 s, 313 respectively. Whereas, the mean aorta diameter, EF, EDV, troponin I, CKP-MB, APTT in 314 patients without elevation in troponin T is 35.31 mm, 54.68%, 134.95 ml, 4.51 ng/ml, 75.26 315 U/l, 27.01 sec, respectively, which is statistically significant difference; t value 2.34, 2.01, 316 2.07, -3.61, -19.34, -2.55, p< 0.020, 0.045, 0.04, 0.0004, 0.00 0.012, respectively. 317 The mean age of patients with an elevated D-dimer level is 68.14 years and the mean age of 318 patients with normal D-dimer level is a 56.60 years, which is statistically significant 319 difference; t value 2.25, p< 0.04. The mean diastolic size of the right ventricle of patients 320 with elevated D-dimer level is 25.93 mm, and mean diastolic size of the right ventricle of 321 patients with normal D-dimer is 29.40 mm, which is statistically significant difference; t 322 value -2.35, p< 0.04. 323 Comparing the dependent variable shows no statistical differences. (Figure 3)
- 324 In terms of correlations, the appendices display the correlation among all the continuous
- 325 variables. (Appendix 1) (Suppl.1)

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350 351

352

353

354

355

356

357

358

359

An interesting correlation between the level of LDL and the diameter of the aorta basement has been observed. (Figure 4.1, 4.2) It has been shown that when the diastolic size of the left ventricle increases, the EF decreases dramatically. (Figure 4) Discussion Post-MI changes include early and late pathophysiological changes, early post-MI complications include ventricular rupture, aneurism, arrythmia, sudden cardiac arrest, and death [24–26]. However, late changes include pericarditis, pneumonitis, pleuritis, and postinfarction cardiosclerosis and dyskinesia [8, 27]. Such manifestations are associated with some laboratory and instrumental changes. Assessment of these changes helps prevent or slow down or at least make a prognosis for patients with MI. The low level of thrombocytes in patients with concomitant CHF returns to the use of antiaggregant and anticoagulants for a long time. The high level of leukocytes in diabetic patients endorses the hypothesis of a mild chronic mild inflammatory syndrome in patients with metabolic syndrome [9, 21, 23, 28]. The high TAG values in diabetic patients are due to lipogenesis from high glucose serum levels and metabolic disorders associated with chronic lipid peroxidation and biogenesis disorders [28, 29]. The dramatic increase in diastolic size of the right ventricle in patients with COPD is an indicator of the stable stage of pulmonary heart, which is associated with pulmonary hypertension and blood stagnation in the pulmonary circulation [30, 31]. Typically, these patients experience coughing and shortness of breath in the background of distress syndrome, fluid accumulation in pulmonary tissue, and impaired ability of pneumocytes to exchange gas. As compensation for respiratory hypoxemia, the elevation of the levels of erythropoietin and the further elevation of erythropoiesis, which is demonstrated in the high level of Hb in patients with COPD. Leukocytosis is observed in patients with varicose veins and is an indicator of persistent inflammation with increased tissue hypoxia and a further increase in the hypoxia inducer factor to stimulate erythropoietin production and an additional increase in the level of red blood cells in patients with varicose veins [32, 33]. This persistent inflammation is confirmed by the elevation of the ESR level in patients with varicose veins [34–37]. Post-MI complications reported in 4/5 of the sample and these complications associated with some laboratory and instrumental changes. Suggesting that post MI laboratory changes are not limited to the local myocardial infarction changes to involves systemic manifestations such as kidney function impairment or development of new kidney disease. These changes 360 include an increase in the aorta diameter at the basement level, an increase in the right 361 ventricle wall, a decrease in the level of RBC, the serum potassium level, and serum calcium 362 level, with an increase in the serum myoglobin. High myoglobin levels are associated with 363 the development of chronic heart failure. 364 Re-infarct worsens the kidney function and induces renal failure [38–41]. Aging is a risk 365 factor for MI and arrythmia development. Arrythmia increases CPK-MB, LDH, AST, 366 diastolic size of both atriums, and decreases EF. The higher the troponin level, the lower the 367 EF, and the fewer further sequalae. 368 An early post-MI aneurysm significantly alters cardiac output and further reduces systemic 369 systolic blood pressure. These changes are associated with the reduction in the blood flow in 370 to the renal afferent fibers, which are sensed by the juxtaglomerular apparatus that leads to 371 activation the renin angiotensin aldosterone system with the anti-diuretic hormone. Therefore, 372 a reduction in kidney function is observed in patients with MI. Additionally, elevation of 373 creatinine in aneurysm patients is typical for impaired kidney function particularly filtration 374 due to hypoperfusion of the glomeruli. The higher creatinine level is associated with the 375 development of arrythmia. Also, the higher LDH is associated with the development of 376 arrythmia. 377 Patients with pneumonitis are having a high leukocyte in serum and in the urine, high ESR, 378 and high CKP-MB fraction. However, these patients experience small diameter of the aorta 379 basement. 380 Conclusions 381 The early prognostic value of the instrumental and laboratory changes is complication 382 dependent. With age, the level of D-dimer and thrombocytes increases. The higher the 383 troponin level, the lower the EF, and the fewer further sequalae. Systemic manifestations 384 include kidney function impairment or development of new kidney disease. These changes 385 include an increase in the diameter of the aorta at the basement level, an increase in the right 386 ventricle wall, a decrease in the level of serum red blood cells, the serum potassium level, and 387 the serum calcium level, with an increase in serum myoglobin. The higher creatinine level is 388 associated with the development of arrythmia. Also, the higher LDH is associated with the 389 development of arrythmia. 390 List of abbreviations 391 CHF; chronic heart failure, DM; Diabetes mellitus, CKD; Chronic kidney disease, COPD; 392 Chronic obstructive pulmonary disease, MI; myocardial infarction, HR; heart rate, ESR; 393 erythrocytes sedimentation rate, RBC; red blood cells

395

396

397

398 399

400

401

402

403

404 405

406

407

408 409

410

411

412413

414

415

416

417 418

419

420 421

422

423

424 425

426

Declarations ETHICS APPROVAL AND CONSENT TO PARTICIPATE The study approved by the National Research Mordovia State University 6 Russia, from "Ethics Committee Requirement N8/2 from 30.06.2022". **HUMAN AND ANIMAL RIGHTS** No animals were used in this research. All human research procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2013. CONSENT FOR PUBLICATION Written informed consent was obtained from the participants for publication of study results and any accompanying images. AVAILABILITY OF DATA AND MATERIALS Applicable on reasonable request. **FUNDING** The work of Basheer Abdullah Marzoog was financed by the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Research Center 'Digital biodesign and personalized healthcare' № 075-15-2022-304. CONFLICT OF INTEREST The authors declare no conflict of interest, financial or otherwise. **ACKNOWLEDGEMENTS** Declared none. **AUTHORS' CONTRIBUTIONS** MB collected the data from the hospital, inserted them into the excel file, analyzed the statistical data, wrote the draft, and revised the final version of the paper. NIB, IAB, NRC,

- 427 and VSG inserted data into the excel file. EIG gave me access to the rehabilitation hospital to
- 428 collect the data. All authors have read and approved the manuscript.

References

- 431 1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-
- Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y, Elkind MS
- V, Evenson KR, Eze-Nliam C, Fugar S, Generoso G, Heard DG, Hiremath S, Ho JE et
- al (2023) Heart Disease and Stroke Statistics-2023 Update: A Report From the
- American Heart Association. Circulation 147:e93–e621.
- https://doi.org/10.1161/CIR.000000000001123
- 437 2. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR,
- Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F,
- Oguz A, Kruger IM, Diaz R, Yusoff K et al (2020) Modifiable risk factors,
- 440 cardiovascular disease, and mortality in 155 722 individuals from 21 high-income,
- 441 middle-income, and low-income countries (PURE): a prospective cohort study. Lancet
- 442 395:795–808. https://doi.org/10.1016/S0140-6736(19)32008-2
- 443 3. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW,
- 444 Gortmaker SL (2019) Projected U.S. State-Level Prevalence of Adult Obesity and
- Severe Obesity. N. Engl. J. Med. 381:2440–2450.
- 446 https://doi.org/10.1056/NEJMSA1909301
- 447 4. Grundy SM (2008) A changing paradigm for prevention of cardiovascular disease:
- emergence of the metabolic syndrome as a multiplex risk factor. Eur. Hear. J. Suppl.
- 449 10:B16–B23. https://doi.org/10.1093/EURHEARTJ/SUM044
- 450 5. Abdullah Marzoog B (2022) Adaptive and Compensatory Mechanisms of the
- 451 Cardiovascular System and Disease Risk Factors in young males and females. New
- Emirates Med. J. 04: https://doi.org/10.2174/04666221128110145
- 453 6. Bays HE, Taub PR, Epstein E, Michos ED, Ferraro RA, Bailey AL, Kelli HM,
- 454 Ferdinand KC, Echols MR, Weintraub H, Bostrom J, Johnson HM, Hoppe KK,
- 455 Shapiro MD, German CA, Virani SS, Hussain A, Ballantyne CM, Agha AM et al
- 456 (2021) Ten things to know about ten cardiovascular disease risk factors. Am. J. Prev.
- 457 Cardiol. 5:100149. https://doi.org/10.1016/J.AJPC.2021.100149
- 458 7. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear
- SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP (2021) Obesity and
- 460 Cardiovascular Disease: A Scientific Statement From the American Heart Association.

- 461 Circulation 143:e984. https://doi.org/10.1161/CIR.0000000000000973
- 462 8. Marzoog BA, Alexandrovich KO, Nikolaevich TM, Vladimirovich KS (2023) Post-
- 463 Coronary Artery Bypass Graft Complications; Potential Causes and Risk Factors.
- 464 medRxiv 2022.12.29.22284005. https://doi.org/10.1101/2022.12.29.22284005
- 465 9. Marzoog BA (2023) Tree of life: endothelial cell in norm and disease, the good guy is
- a partner in crime! Anat Cell Biol. https://doi.org/10.5115/acb.22.190
- 10. Tian X, Chen S, Wang P, Xu Q, Zhang Y, Luo Y, Wu S, Wang A (2022) Insulin
- resistance mediates obesity-related risk of cardiovascular disease: a prospective cohort
- study. Cardiovasc. Diabetol. 21:289. https://doi.org/10.1186/s12933-022-01729-9
- 470 11. Lavie CJ, Ozemek C, Carbone S, Katzmarzyk PT, Blair SN (2019) Sedentary
- Behavior, Exercise, and Cardiovascular Health. Circ. Res. 124:799–815.
- 472 https://doi.org/10.1161/CIRCRESAHA.118.312669
- Lorber D (2014) Importance of cardiovascular disease risk management in patients
- with type 2 diabetes mellitus. Diabetes, Metab. Syndr. Obes. 7:169–183.
- https://doi.org/10.2147/DMSO.S61438
- 476 13. Marzoog BA (2022) Autophagy in endothrlial cell dysfunction. Curr Mol Med
- 477 14. Marzoog BA (2023) Endothelial cell autophagy in the context of disease development.
- 478 Anat. Cell Biol. 56:16–24. https://doi.org/10.5115/acb.22.098
- 479 15. Marzoog BA (2023) Transcription Factors the Essence of Heart Regeneration: A
- 480 Potential Novel Therapeutic Strategy. Curr. Mol. Med. 23:232–238.
- 481 https://doi.org/10.2174/1566524022666220216123650
- 482 16. Marzoog BA (2023) Autophagy Behavior in Post-myocardial Infarction Injury.
- 483 Cardiovasc. Hematol. Disord. Targets 23:.
- https://doi.org/10.2174/1871529X23666230503123612
- 485 17. Marzoog BA (2022) Recent advances in molecular biology of metabolic syndrome
- pathophysiology: endothelial dysfunction as a potential therapeutic target. J. Diabetes
- 487 Metab. Disord. 21:1903–1911. https://doi.org/10.1007/s40200-022-01088-y
- 488 18. Marzoog BA, Vlasova TI (2021) Membrane lipids under norm and pathology. Eur. J.
- 489 Clin. Exp. Med. 19:59–75. https://doi.org/10.15584/ejcem.2021.1.9
- 490 19. Marzoog B (2021) Lipid Behavior in Metabolic Syndrome Pathophysiology. Curr.
- 491 Diabetes Rev. 18:. https://doi.org/10.2174/1573399817666210915101321
- 492 20. Abdullah Marzoog B (2023) Caveolae's Behavior in Norm and Pathology. New
- Emirates Med. J. 04: https://doi.org/10.2174/0250688204666230508112229
- 494 21. Marzoog BA (2023) The Metabolic Syndrome Puzzles; Possible Pathogenesis and

- 495 Management. Curr. Diabetes Rev. 19:59–66.
- 496 https://doi.org/10.2174/1573399818666220429100411
- 497 22. Marzoog BA, Vlasova TI (2022) Myocardiocyte autophagy in the context of
- myocardiocytes regeneration: a potential novel therapeutic strategy. Egypt. J. Med.
- 499 Hum. Genet. 23:41. https://doi.org/10.1186/s43042-022-00250-8
- 500 23. Marzoog BA, Vlasova TI (2022) Beta-cell autophagy under the scope of hypoglycemic
- drugs; possible mechanism as a novel therapeutic target. Obe. Metab. 18:465–470.
- 502 https://doi.org/10.14341/omet12778
- 503 24. Damluji AA, Van Diepen S, Katz JN, Menon V, Tamis-Holland JE, Bakitas M, Cohen
- MG, Balsam LB, Chikwe J (2021) Mechanical Complications of Acute Myocardial
- 505 Infarction: A Scientific Statement From the American Heart Association. Circulation
- 506 144:E16–E35. https://doi.org/10.1161/CIR.000000000000985
- 507 25. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE (2011) Left ventricular
- remodeling in heart failure: Current concepts in clinical significance and assessment.
- JACC Cardiovasc. Imaging 4:98–108. https://doi.org/10.1016/J.JCMG.2010.10.008
- 510 26. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio
- ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ,
- 512 Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P et al (2018)
- 513 2017 ESC Guidelines for the management of acute myocardial infarction in patients
- presenting with ST-segment elevation. Eur. Heart J. 39:119–177.
- 515 https://doi.org/10.1093/EURHEARTJ/EHX393
- 516 27. Elbadawi A, Elgendy IY, Mahmoud K, Barakat AF, Mentias A, Mohamed AH,
- 517 Ogunbayo GO, Megaly M, Saad M, Omer MA, Paniagua D, Abbott JD, Jneid H
- 518 (2019) Temporal Trends and Outcomes of Mechanical Complications in Patients With
- 519 Acute Myocardial Infarction. JACC Cardiovasc. Interv. 12:1825–1836.
- 520 https://doi.org/10.1016/J.JCIN.2019.04.039
- 521 28. Marzoog B (2022) Lipid Behavior in Metabolic Syndrome Pathophysiology. Curr.
- 522 Diabetes Rev. 18:e150921196497.
- 523 https://doi.org/10.2174/1573399817666210915101321
- 524 29. Glowinski J, Glowinski S (2002) Generation of reactive oxygen metabolites by the
- varicose vein wall. Eur. J. Vasc. Endovasc. Surg. 23:550–555.
- 526 https://doi.org/10.1053/EJVS.2002.1656
- 527 30. Marzoog BA (2022) Pulmonary Fibrosis; Risk Factors and Molecular Triggers, Insight
- for Neo Therapeutic Approach. Curr. Respir. Med. Rev. 18:259–266.

- 529 https://doi.org/10.2174/1573398X18666220806124019
- 530 31. Marzoog BA (2023) Local Lung Fibroblast Autophagy in the Context of Lung Fibrosis
- Pathogenesis. Curr. Respir. Med. Rev. 19:6–11.
- https://doi.org/10.2174/1573398X19666221130141600
- 533 32. Poredos P, Spirkoska A, Rucigaj T, Fareed J, Jezovnik MK (2015) Do Blood
- Constituents in Varicose Veins Differ From the Systemic Blood Constituents?
- 535 https://doi.org/10.1016/j.ejvs.2015.04.031
- 536 33. Lattimer CR, Kalodiki E, Geroulakos G, Hoppensteadt D, Fareed J (2016) Are
- Inflammatory Biomarkers Increased in Varicose Vein Blood? Clin. Appl. Thromb.
- 538 22:656–664.
- https://doi.org/10.1177/1076029616645330/ASSET/IMAGES/LARGE/10.1177_1076
- 540 029616645330-FIG2.JPEG
- 541 34. Bontekoe E, Brailovsky Y, Hoppensteadt D, Bontekoe J, Siddiqui F, Newman J, Iqbal
- 542 O, Reed T, Fareed J, Darki A (2021) Upregulation of Inflammatory Cytokines in
- Pulmonary Embolism Using Biochip-Array Profiling. Clin. Appl. Thromb. 27:.
- 544 https://doi.org/10.1177/10760296211013107
- 545 35. Dzieciuchowicz L, Espinosa G, Páramo JA (2015) Increased levels of
- metalloproteinase 10 and hemostatic markers in patients with noncomplicated primary
- varicose veins. Clin. Appl. Thromb. 21:684–687.
- 548 https://doi.org/10.1177/1076029613517167
- 549 36. Gwozdzinski L, Pieniazek A, Bernasinska-Slomczewska J, Hikisz P, Gwozdzinski K
- 550 (2021) Alterations in the Plasma and Red Blood Cell Properties in Patients with
- Varicose Vein: A Pilot Study. Cardiol. Res. Pract. 2021:1–10.
- 552 https://doi.org/10.1155/2021/5569961
- 553 37. Jezovnik MK, Fareed J, Poredos P (2017) Patients with a History of Idiopathic Deep
- Venous Thrombosis Have Long-Term Increased Levels of Inflammatory Markers and
- Markers of Endothelial Damage. Clin. Appl. Thromb. 23:124–131.
- 556 https://doi.org/10.1177/1076029616670259
- 557 38. Wang C, Pei YY, Ma YH, Ma XL, Liu ZW, Zhu JH, Li CS (2019) Risk factors for
- acute kidney injury in patients with acute myocardial infarction. Chin. Med. J. (Engl).
- 559 132:1660. https://doi.org/10.1097/CM9.0000000000000293
- 560 39. Shacham Y, Leshem-Rubinow E, Steinvil A, Assa E Ben, Keren G, Roth A, Arbel Y
- 561 (2014) Renal impairment according to acute kidney injury network criteria among ST
- elevation myocardial infarction patients undergoing primary percutaneous

563 intervention: A retrospective observational study. Clin. Res. Cardiol. 103:525–532. 564 https://doi.org/10.1007/S00392-014-0680-8 40. 565 Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, Kosiborod M, 566 Amin AP, Messenger JC, Rumsfeld JS, Spertus JA (2014) Contemporary incidence, 567 predictors, and outcomes of acute kidney injury in patients undergoing percutaneous 568 coronary interventions: Insights from the NCDR cath-PCI registry. JACC Cardiovasc. 569 Interv. 7:1–9. https://doi.org/10.1016/J.JCIN.2013.06.016 570 41. Maksimczuk J, Galas A, Krzesiński P (2022) What Promotes Acute Kidney Injury in Patients with Myocardial Infarction and Multivessel Coronary Artery 571 572 Disease— Contrast Media, Hydration Status or Something Else? Nutr. 2023, 573 Vol. 15, Page 21 15:21. https://doi.org/10.3390/NU15010021

Figure legend

574 575

576 577




Figure 1: Cut-off point for the age of the patients divided into male and female. Males are less than 67 years old. However, the female affected at more than 67 years of age.




Figure 2: Diagramed presentation of the concomitant and the post MI compilations. From below complications (CHF, DM, hypertension, CKD, COPD, dyslipidaemia, varicose veins) belong to concomitant diseases before the development of MI. Abbreviations: CHF; chronic heart failure, COPD; chronic obstructive pulmonary disease, CKD; chronic kidney disease, DM; diabetes mellites.




Figure 3: Graphical presentation of the dynamical changes in the levels of LDH (lactate dehydrogenase) and CPK-MB (creatinine phosphokinase-MB fraction). Both LDH and CPK-

MB fraction measured by U/L. this analysis conducted between two days for all patients as a follow up after MI.




Figure 4.1 and 4.2: A direct correlation between LDL level and the aorta diameter. Furthermore, an opposite correlation between the left ventricle (LV) diastolic size and the EF.

All these charts have a statistically significant correlation

